Amlodipine + perindopril versus atenolol + bendroflumethiazide in hypertensive patients with hyperlipidaemia with or without atorvastatin.

Trial Profile

Amlodipine + perindopril versus atenolol + bendroflumethiazide in hypertensive patients with hyperlipidaemia with or without atorvastatin.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Atorvastatin (Primary) ; Amlodipine; Atenolol; Bendroflumethiazide; Perindopril
  • Indications Cardiovascular disorders; Coronary artery disease; Essential hypertension; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ASCOT; ASCOT-10; ASCOT-BPLA; ASCOT-LLA; CAFE; CAFE-DIABETES; CARAT; EVIREST
  • Most Recent Events

    • 30 Aug 2017 Results of post hoc analysis of ASCOT lipid lowering arm evaluating safety and efficacy among patients treated with amlodipine, perindopril atorvastatin or placebo presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 02 Sep 2015 Substudy results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
    • 08 Feb 2015 Accrual to date is 100% according to United Kingdom Clinical Research Network
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top